For more than 15 years, CSG as an independent contract research organization has been supporting clients from the pharmaceutical sector, the fields of biotechnology and medical device manufactoring in planning, implementing and analyzing clinical-scientific studies. Due to our long-term experience and our employees’ know-how as well as the usage of state-of-the-art technologies, CSG ensures the cost- and time-effective implementation of projects. The focus lies on the following study types:
Clinical trials for pharmaceuticals
The implementation of clinical trials to assess the effectiveness and safety of pharmaceuticals before, during and after authorization is subject to strict and constantly changing statutory, regulatory and ethical requirements.
As a competent partner, CSG supports clients in the successful implementation of the following studies:
- Phase II and III trials
- Phase IV trials
- Non-commercial trials (IITs – Investigator Initiated Trial)
Non-interventional studies of pharmaceuticals
An evidence-based proof of benefits of pharmaceuticals is of major importance for the use and reimbursement of such products. In addition to clinical testing, well-planned trials of authorized pharmaceuticals can provide important insights under routine conditions.
CSG offers tailor-made concepts for the implementation of the following studies:
- Observational studies (PMS – Post-Marketing Surveillance) - Prospective cohort studies, Retrospective case-control studies, Cross-sectional studies
- Safety evaluations (PASS – Post-Authorization Safety Study)
Clinical trials for medical devices
Due to the growing statutory requirements in the framework of the clinical assessment for the authorization and the proof of benefits of a medical device, the implementation of clinical trials is gaining in importance.
CSG assists clients successfully when implementing the following studies:
- Interventional studies (§§19-23a MPG)
- Non-interventional studies (§23b MPG)
- Non-commercial trials (IITs – Investigator Initiated Trial)
Biomarker studies
The development of new biomarkers for the diagnosis of diseases and the prognostic estimation for potential individual treatment strategies increasingly gained importance in the course of the last years. Scientific studies to identify and validate biomarkers are governed by specific regulatory and data protection requirements. Subject to the adherence to the good clinical practice, CSG offers competent concepts for the implementation of such studies:
- Regulatory requirements for sample collection studies
- Data collection in sample collection studies
- Logistics for sample collection studies
- Data protection / data trusteeship at biobanks